Bonesupport Holding

Bonesupport’s stock rose about 35% within a month, supported by improved reimbursement in the US from CMS for the antibiotic-containing bone substitute CERAMENT G. Analysts at ABG Sundal Collier expect an organic sales increase of 31% for Q1; results will be published on April 22. CEO Torbjörn Sköld confirms the 2026 guidance of more than 35% revenue growth, driven by further market penetration in foot/ankle, trauma and revision arthroplasty. Technically, the stock has moved above the 200-day moving average; investors are holding positions and betting on strong quarterly figures. » Plus sur deraktionaer.de

Bonesupport reports a Q4 2025 revenue increase of 36% to SEK 313 million and records a sales increase of nearly 40% for 2025 overall. The company issues guidance for 2026 of at least 35% revenue growth at constant exchange rates and cites strong demand in the US for CERAMENT products as well as potential from indication expansions. Gross margins are typically around 90%; the stock rises by almost 20% after the outlook and reaches its highest level since October. » Plus sur deraktionaer.de

Bonesupport reported Q3 2025 net sales of SEK 294.1m (+24% yoy; +34% currency-adjusted) and an adjusted operating margin of 27%, driven by a strong US business and growth in the antibiotic-releasing CERAMENT products. Operating cash flow remained robust and net cash stood at SEK 379.0m at quarter-end. The company is preparing market entries in spine surgery and revision arthroplasty, received NTAP approval for CERAMENT G and reiterated full-year guidance of >40% currency-adjusted revenue growth. Despite operational progress, the stock fell sharply after the presentation, reflecting investor concerns about currency headwinds, possible regulatory hurdles and market risks. » Plus sur de.investing.com